The abstract is read at the publisher; the summary is JClub's.
In fee-for-service Medicare patients with incident cancer (2014–2020), oncologists’ guideline-preferred drug payments were linked to higher receipt of preferred treatment (RR=1.06).
- Why it matters: Industry payments may shape prescribing, but whether they affect patients’ likelihood of receiving guideline-preferred cancer care was unclear.
- What they did: Using Medicare claims, the study matched 15,607 patients across 14 cancer scenarios to NCCN guideline-preferred treatments at diagnosis, then related outcomes to oncologist payments in the prior year.
- The result: After adjustment, payments for guideline-preferred treatment increased preferred-treatment receipt (RR=1.06, 95% CI 1.01–1.13), while nonpreferred payments decreased it (RR=0.93, 95% CI 0.89–0.98), with stronger associations at higher payment values.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.